Replies to post #158324 on Biotech Values

[poorgradstudent]

So O'Karma's gone and you figure, what...That all his hencemen were not aware of the shenanigans? That GERN has turned over a new leaf? OK so forgetabout the mirkyness...Things are different now I guess.

No. More that they're now not chasing a pipe dream with their stem cell assets and that they could have competently followed up on promising early data using a directed inhibitor.

Companies with failure in their past do change behaviour if/when they get compelling data*. I was willing to take a risk with Gern and made prospective decisions on what to buy and what to sell when. I'm just sticking to the system I have, and it has nothing to do with O'Karma. I came, I saw, and I've adjusted accordingly.


* See PCYC (Xcytrin), INCY / MLNM (genomics anyone?), ONXX (Onyx-015), ARIA (litigating over NF-Kappa-B)